SBN is a decent Bio tech shell play capped at $2.5m with $1.1m cash and a very low cash burn of about $150k a qtr
They've been looking at doing a bio tech deal for awhile now and almost pulled one off in December last year to do with some heart valve technology
SBN reminds me of PIE which I bought under 4c when they made it clear they were looking at new tech opportunities it took 6months but PIE gave 4 bagger returns when they acquired a new tech project but I told most too early when it doubled up and then tripled up
OZB was a good one recently when you joined the dots about the new guy who got appointed and the recent deals they had done like MYA RCM and SFP
